Lehrstuhl für Haut- und Geschlechtskrankheiten

Brief Communication: Treatment Outcomes for Advanced Melanoma of Unknown Primary Compared With Melanoma With Known Primary (2024) Persa OD, Cecile Hassel J, Steeb T, Erdmann M, Karimi B, Stege H, Klespe KC, et al. Journal article A Hybrid Type III Effectiveness-Implementation Trial to Optimize Medication Safety With Oral Antitumor Therapy in Real-World: The AMBORA Competence and Consultation Center. (2024) Cuba L, Dürr P, Geßner K, Häcker B, Fietkau R, Siebler J, Pavel ME, et al. Journal article Electroporation of mRNA as a Universal Technology Platform to Transfect a Variety of Primary Cells with Antigens and Functional Proteins (2024) Sauerer T, Albrecht L, Sievers NM, Gerer KF, Hoyer S, Dörrie J, Schaft N Book chapter / Article in edited volumes Efficacy of interventions for cutaneous squamous cell carcinoma in situ (Bowen's disease): A systematic review and meta-analysis of proportions (2024) Petzold A, Wessely A, Steeb T, Berking C, Heppt M Journal article, Review article Acod1-mediated inhibition of aerobic glycolysis suppresses osteoclast differentiation and attenuates bone erosion in arthritis (2024) Kachler K, Andreev D, Thapa S, Royzman D, Gießl A, Karuppusamy S, Llerins Perez M, et al. Journal article Influence of adjuvant therapies on organ-specific recurrence of cutaneous melanoma: A multicenter study on 1383 patients of the prospective DeCOG registry ADOReg (2024) Wohlfeil SA, Kranzmann L, Weiß C, von Wasielewski I, Klespe KC, Kähler KC, Weichenthal M, et al. Journal article Optimizing immune checkpoint blockade in metastatic uveal melanoma: exploring the association of overall survival and the occurrence of adverse events (2024) Koch E, Petzold A, Dippel E, Erdmann M, Gesierich A, Gutzmer R, Hassel JC, et al. Journal article The Current State of Systemic Therapy of Metastatic Uveal Melanoma (2024) Koch E, Heppt M, Berking C Journal article Stringent monitoring can decrease mortality of immune checkpoint inhibitor induced cardiotoxicity (2024) Wang Y, Ertl C, Schmitt C, Hammann L, Kramer R, Grabmaier U, Schöberl F, et al. Journal article Guselkumab demonstrates long-term efficacy and maintenance of treatment response postwithdrawal in systemic treatment-naïve patients and nonresponders to fumaric acid esters: results from parts II and III of a randomized active-comparator-controlled phase IIIb trial (POLARIS). (2024) Thaçi D, Pinter A, Sebastian M, Termeer C, Sticherling M, Gerdes S, Schäkel K, et al. Journal article